文献速递泌尿男性生殖肿瘤

局限性前列腺癌常规与中度大分割放疗随机试验十年更新

Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2020-03-02

单中心随机前瞻试验比较常规分割IMRT(76 Gy/38次)与中度大分割IMRT(70.2 Gy/26次)治疗中高危前列腺癌,303例可评估患者中位随访122.9个月。10年BCDF累积发生率两组无显著差异(25.9% vs 30.6%,HR 1.31,95%CI 0.82-2.11),但大分割组10年远处转移累积发生率更高(率差7.8%,95%CI 0.7%-15.1%)。大分割IMRT未能显示优于常规分割的长期疾病结局。

要点

  • 10年BCDF累积发生率常规分割组25.9%,大分割组30.6%,差异无统计学意义。
  • 大分割组10年远处转移累积发生率较常规分割组高7.8%(95%CI 0.7%-15.1%)。
  • 两组前列腺癌特异性死亡和总死亡率相似,大分割未显示长期优势。

核心结论

  • 中度大分割IMRT在长期疾病结局上未能证明优于常规分割IMRT。
  • 大分割组10年远处转移累积发生率更高,需关注长期远处转移风险。

研究设计与样本

  • 单中心随机前瞻性试验,纳入协议定义的中危和高危前列腺腺癌男性。
  • 303例可评估患者随机接受常规分割IMRT(76 Gy/38次)或中度大分割IMRT(70.2 Gy/26次)。
  • 高危患者均接受24个月ADT和淋巴结照射,中危患者由医生决定是否接受4个月ADT。
  • 主要终点为BCDF累积发生率,中位随访122.9个月。

主要发现

  • 按更新NCCN风险分类,低危28例(9.2%)、中危189例(62.4%)、高危86例(28.4%)。
  • 10年BCDF累积发生率常规分割组25.9%,大分割组30.6%(HR 1.31;95%CI 0.82-2.11)。
  • 两组10年生化失败、前列腺癌特异性死亡和总死亡率相似。
  • 大分割组10年远处转移累积发生率更高(率差7.8%;95%CI 0.7%-15.1%)。

临床怎么用

  • 在中高危局限性前列腺癌中,中度大分割IMRT不应常规替代常规分割IMRT作为标准推荐。
  • 选择大分割方案时需充分告知患者长期远处转移风险可能增加。

局限性

  • 单中心研究,样本量303例,可能限制统计效能和普遍性。
  • 常规分割组黑人患者比例更高(17.8% vs 7.3%;P = .02),组间存在不平衡。
  • 中危患者ADT使用由医生决定,可能引入混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The previously published single institution randomized prospective trial failed to show superiority in the 5-year biochemical and/or clinical disease failure (BCDF) rate with moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) versus conventionally fractionated IMRT (C-IMRT). We now present 10-year disease outcomes using updated risk groups and definitions of biochemical failure. METHODS: Men with protocol-defined intermediate- and high-risk prostate adenocarcinoma were randomly assigned to receive C-IMRT (76 Gy in 38 fractions) or H-IMRT (70.2 Gy in 26 fractions). Men with high-risk disease were all prescribed 24 months of androgen deprivation therapy (ADT) and had lymph node irradiation. Men with intermediate risk were prescribed 4 months of ADT at the discretion of the treating physician. The primary endpoint was cumulative incidence of BCDF. We compared disease outcomes and overall mortality by treatment arm, with sensitivity analyses for National Comprehensive Cancer Network (NCCN) risk group adjustment. RESULTS: Overall, 303 assessable men were randomly assigned to C-IMRT or H-IMRT. The median follow-up was 122.9 months. Per updated NCCN risk classification, there were 28 patients (9.2%) with low-risk, 189 (62.4%) with intermediate-risk, and 86 (28.4%) with high-risk prostate cancer. The arms were equally balanced for clinicopathologic factors, except that there were more black patients in the C-IMRT arm (17.8% v 7.3%; P = .02). There was no difference in ADT use (P = .56). The 10-year cumulative incidence of BCDF was 25.9% in the C-IMRT arm and was 30.6% in the H-IMRT arm (hazard ratio, 1.31; 95% CI, 0.82 to 2.11). The two arms also had similar cumulative 10-year rates of biochemical failure, prostate cancer-specific mortality, and overall mortality; however, the 10-year cumulative incidence of distant metastases was higher in the H-IMRT arm (rate difference, 7.8%; 95% CI, 0.7% to 15.1%). CONCLUSION: H-IMRT failed to demonstrate superiority compared with C-IMRT in long-term disease outcomes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Avkshtol V, Ruth KJ, Ross EA, et al. Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer. J Clin Oncol. 2020. PMID: 32119599. doi:10.1200/JCO.19.01485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。